Vectorius’s Implantable Heart Failure Sensor: A Game-Changer in Self-Management and Improved Quality of Life

Vectorius, a cutting-edge Israeli start-up company, has developed a revolutionary tiny pressure sensor that is implanted in the heart. This minuscule device, which measures just 3 mm and does not require a battery, enables heart failure patients to self-manage their condition with precision. Heart failure is a complex and prevalent disease among heart conditions. By using a dedicated application and relying on data from the heart, patients can adjust their medication dosage, thus preventing disease deterioration, repeated hospitalizations, and improving their quality of life.

Recently, a pilot study examined the safety, usability, and performance of the system and therapeutic paradigm created by Vectorius. The results were promising: self-management of heart failure patients based on left atrium pressure is safe and effective. There were no complications or side effects related to the system or self-treatment after 12 months of follow-up. The sensor’s stability and accuracy remained consistent throughout, with patients showing high levels of cooperation for treatment leading to significant improvements in quality of life indicators and reduced hospitalizations due to heart failure.

The observed clinical effect is attributed to most patients avoiding very high left ventricle pressures, which can lead to issues like pulmonary congestion and edema requiring hospitalization. Additionally, transferring control to the patient has a positive behavioral component in enhancing treatment effects. Patients receiving immediate feedback were able to balance their medication and lifestyle effectively.

Vectorius already has 55 transplant recipients in Israel and Europe with over 40,000 cumulative follow-up days. This summer, transplants are planned at top heart centers in the US as part of the ongoing expansion of the clinical trial. Eyal Orion, co-founder and CEO of Vectorius, sees the publication of the research as a historic milestone for the company, which has been developing advanced technology and a new therapeutic method for over a decade. The company aims to fundamentally change the understanding and treatment of heart diseases, positioning Israel as a pioneer in the field with a significant impact on millions of patients worldwide.

Established in 2011 by Dr. Eyal Orion and Oren Goldstein, Vectorius has 100 employees in Israel